These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26322366)

  • 1. [Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms].
    Kirnichnaya KA; Sosin DN; Ivanov MV; Mikhaylov VA; Ivashchenko DV; Ershov EE; Taraskina AE; Nasyrova RF; Krupitsky EM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(4):113-125. PubMed ID: 26322366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.
    Mas S; Gassó P; Lafuente A; Bioque M; Lobo A; Gonzàlez-Pinto A; Olmeda MS; Corripio I; Llerena A; Cabrera B; Saiz-Ruiz J; Bernardo M;
    Pharmacogenomics J; 2016 Oct; 16(5):439-45. PubMed ID: 27272046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applicability of gene expression and systems biology to develop pharmacogenetic predictors; antipsychotic-induced extrapyramidal symptoms as an example.
    Mas S; Gassó P; Lafuente A
    Pharmacogenomics; 2015 Nov; 16(17):1975-88. PubMed ID: 26556470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway.
    Mas S; Gassó P; Ritter MA; Malagelada C; Bernardo M; Lafuente A
    Eur Neuropsychopharmacol; 2015 Jan; 25(1):51-9. PubMed ID: 25499605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms.
    Boloc D; Rodríguez N; Torres T; García-Cerro S; Parellada M; Saiz-Ruiz J; Cuesta MJ; Bernardo M; Gassó P; Lafuente A; Mas S; Arnaiz JA
    Psychopharmacology (Berl); 2020 Jul; 237(7):2151-2159. PubMed ID: 32382784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Network analysis of gene expression in peripheral blood identifies mTOR and NF-κB pathways involved in antipsychotic-induced extrapyramidal symptoms.
    Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
    Pharmacogenomics J; 2015 Oct; 15(5):452-60. PubMed ID: 25623440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized antipsychotic treatment: the adverse effects perspectives.
    Plesnicar BK
    Psychiatr Danub; 2010 Jun; 22(2):329-34. PubMed ID: 20562775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes.
    Gassó P; Mas S; Crescenti A; Alvarez S; Parramon G; Garcia-Rizo C; Parellada E; Bernardo M; Lafuente A
    Psychiatry Res; 2010 Jan; 175(1-2):173-5. PubMed ID: 19892410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and antipsychotic treatment response.
    Naumovska Z; Nestorovska AK; Filipce A; Sterjev Z; Brezovska K; Dimovski A; Suturkova LJ
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):53-67. PubMed ID: 26076775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
    Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
    J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: Avoiding intolerance to antipsychotics through a personalized treatment approach based on pharmacogenetics.
    Korošec Hudnik L; Blagus T; Redenšek Trampuž S; Dolžan V; Bon J; Pjevac M
    Front Psychiatry; 2024; 15():1363051. PubMed ID: 38566958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE).
    Fischer-Barnicol D; Lanquillon S; Haen E; Zofel P; Koch HJ; Dose M; Klein HE;
    Neuropsychobiology; 2008; 57(1-2):80-7. PubMed ID: 18515977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.
    Gassó P; Mas S; Bernardo M; Alvarez S; Parellada E; Lafuente A
    Pharmacogenomics J; 2009 Dec; 9(6):404-10. PubMed ID: 19506579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genetic dissection of antipsychotic induced movement disorders.
    Crisafulli C; Drago A; Sidoti A; Serretti A
    Curr Med Chem; 2013; 20(3):312-30. PubMed ID: 23157623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome.
    Tandon R; Jibson MD
    Ann Clin Psychiatry; 2002 Jun; 14(2):123-9. PubMed ID: 12238737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
    Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
    Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms.
    Mas S; Gassó P; Boloc D; Rodriguez N; Mármol F; Sánchez J; Bernardo M; Lafuente A
    Pharmacogenomics J; 2016 Jun; 16(3):293-300. PubMed ID: 26122020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National prescribing patterns in the management of extrapyramidal symptoms among patients with schizophrenia.
    Luo RD; Belleti DA; Tran D; Arcona S; Salen PN
    Int J Psychiatry Med; 2002; 32(3):261-9. PubMed ID: 12489701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.
    Hedenmalm K; Güzey C; Dahl ML; Yue QY; Spigset O
    J Clin Psychopharmacol; 2006 Apr; 26(2):192-7. PubMed ID: 16633151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.
    Basile VS; Masellis M; McIntyre RS; Meltzer HY; Lieberman JA; Kennedy JL
    J Clin Psychiatry; 2001; 62 Suppl 23():45-66. PubMed ID: 11603885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.